<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202667</url>
  </required_header>
  <id_info>
    <org_study_id>2017-00701</org_study_id>
    <nct_id>NCT03202667</nct_id>
  </id_info>
  <brief_title>Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study</brief_title>
  <acronym>SANDx</acronym>
  <official_title>Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of
      antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water
      retention and secondary natriuresis and is a common cause for hyponatremia.

      Especially chronic (&gt;72h) SIADH is difficult to treat as standard therapeutic options (water
      restriction, urea, salt tablets) often do not succeed in correction of hyponatremia, making
      additional therapy necessary.

      Empagliflozin is a sodium glucose co-transporter 2 (SGLT2)-inhibitor, which is a
      well-tolerated treatment option for type 2 diabetes mellitus. The inhibition of SGLT2 in the
      proximal tubule leads to renal excretion of glucose with subsequent osmotic diuresis. This
      mechanism could result in a therapeutic effect in patients with chronic SIADH, as it
      resembles the aquaretic effect of urea.

      The aim of this study is to evaluate whether empagliflozin has an effect on the serum sodium
      levels of patients with chronic SIADH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Sodium concentration</measure>
    <time_frame>28 days</time_frame>
    <description>Difference in serum sodium concentration in mmol/l after 28 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum sodium concentration</measure>
    <time_frame>21 days</time_frame>
    <description>Serum sodium concentration 1, 2 and 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum electrolytes</measure>
    <time_frame>28 days</time_frame>
    <description>Serum electrolytes after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes</measure>
    <time_frame>7 days</time_frame>
    <description>Urinary electrolytes after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes</measure>
    <time_frame>14 days</time_frame>
    <description>Urinary electrolytes after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes</measure>
    <time_frame>21 days</time_frame>
    <description>Urinary electrolytes after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes</measure>
    <time_frame>28 days</time_frame>
    <description>Urinary electrolytes after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osmolality</measure>
    <time_frame>7 days</time_frame>
    <description>Serum osmolality after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osmolality</measure>
    <time_frame>14 days</time_frame>
    <description>Serum osmolality after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osmolality</measure>
    <time_frame>21 days</time_frame>
    <description>Serum osmolality after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osmolality</measure>
    <time_frame>28 days</time_frame>
    <description>Serum osmolality after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary osmolality</measure>
    <time_frame>7 days</time_frame>
    <description>Urinary osmolality after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary osmolality</measure>
    <time_frame>14 days</time_frame>
    <description>Urinary osmolality after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary osmolality</measure>
    <time_frame>21 days</time_frame>
    <description>Urinary osmolality after3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary osmolality</measure>
    <time_frame>28 days</time_frame>
    <description>Urinary osmolality after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose</measure>
    <time_frame>7 days</time_frame>
    <description>Serum glucose after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose</measure>
    <time_frame>14 days</time_frame>
    <description>Serum glucose after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose</measure>
    <time_frame>21 days</time_frame>
    <description>Serum glucose after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose</measure>
    <time_frame>28 days</time_frame>
    <description>Serum glucose after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose</measure>
    <time_frame>7 days</time_frame>
    <description>Urinary glucose after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose</measure>
    <time_frame>14 days</time_frame>
    <description>Urinary glucose after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose</measure>
    <time_frame>21 days</time_frame>
    <description>Urinary glucose after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose</measure>
    <time_frame>28 days</time_frame>
    <description>Urinary glucose after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma copeptin after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma copeptin after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma copeptin after3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma copeptin after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma aldosterone after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma aldosterone after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma aldosterone after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma aldosterone after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma renin after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma renin after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma renin after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma renin after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR-proANP</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma MR-proANP after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR-proANP</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma MR-proANP after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR-proANP</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma MR-proANP after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR-proANP</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma MR-proANP after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N terminal (NT)-proBNP</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma NT-proBNP after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma NT-proBNP after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma NT-proBNP after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma NT-proBNP after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma P1NP after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma P1NP after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma P1NP after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma P1NP after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTx</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma CTx after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTx</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma CTx after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTx</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma CTx after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTx</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma CTx after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma Osteocalcin after 1 week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>14 days</time_frame>
    <description>Plasma Osteocalcin after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>21 days</time_frame>
    <description>Plasma Osteocalcin after 3 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>28 days</time_frame>
    <description>Plasma Osteocalcin after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General well being (assessed by VAS)</measure>
    <time_frame>28 days</time_frame>
    <description>General well being after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache (assessed by VAS)</measure>
    <time_frame>28 days</time_frame>
    <description>Headache after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertigo (assessed by VAS)</measure>
    <time_frame>28 days</time_frame>
    <description>vertigo after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea (assessed by VAS)</measure>
    <time_frame>28 days</time_frame>
    <description>Nausea after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaise (assessed by VAS)</measure>
    <time_frame>28 days</time_frame>
    <description>Malaise after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>28 days</time_frame>
    <description>Body weight after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (mmHg)</measure>
    <time_frame>28 days</time_frame>
    <description>Blood pressure after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (bpm)</measure>
    <time_frame>28 days</time_frame>
    <description>Heart rate after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function (assessed by MOCA)</measure>
    <time_frame>28 days</time_frame>
    <description>change in Neurocognitive function (baseline versus after 4 weeks of Treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength (measured by grip strength test)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in Muscle strength (baseline vs after 4 weeks of Treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Dynamics (measured by gait Analysis)</measure>
    <time_frame>28 days</time_frame>
    <description>Gait dynamics baseline vs after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Parameters (measured by thoracic electrical bioimpedance)</measure>
    <time_frame>28 days</time_frame>
    <description>Hemodynamic parameters baseline vs after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fluid volume (measured by bioimpedance spectroscopy)</measure>
    <time_frame>28 days</time_frame>
    <description>Body fluid volume baseline vs after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Fluid intake in ml</measure>
    <time_frame>28 days</time_frame>
    <description>Fluid intake after 1, 2, 3 and 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Falls</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of falls during observation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of Fractures</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of fractures during observation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of Hospital admissions</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of Hospital admissions during observation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyponatremia recurrence</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of hyponatremia recurrence during 30day follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>SIAD - Syndrome of Inappropriate Antidiuresis</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with empagliflozin 25mg tablets once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with Placebo tablets once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25mg</intervention_name>
    <description>Treatment with empagliflozin 25mg once daily for 28 days</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment with Placebo oral tablet once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients (age ≥ 18 years) with hyponatremia (&lt;133mmol/l) due to chronic (&gt;72h) SIADH
        defined as

          -  serum osmolality &lt;275mosm/kg

          -  urine osmolality &gt;100mosm/kg

          -  urine sodium &gt;30mmol/l

        Exclusion Criteria:

          -  acute (&lt;72h) or transient hyponatremia

          -  severe symptomatic hyponatremia in need of hospital treatment

          -  diabetes mellitus type 1

          -  uncontrolled hypothyroidism

          -  uncontrolled adrenal insufficiency

          -  renal impairment (GFR &lt;45ml/min)

          -  cardiac failure

          -  symptomatic liver disease / severe hepatic impairment (ALAT / aspartate transaminase
             (ASAT) &gt; 3x upper limit)

          -  treatment with SGLT 2 inhibitors, lithium chloride, urea or glitazone

          -  severe immunosuppression

          -  pregnancy or breastfeeding

          -  palliative situation (end of life care)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjam Christ-Crain, Prof. Dr. MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hopsital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Refardt, Dr. MD</last_name>
    <phone>+41(0)61 2652525 Zentrale</phone>
    <email>Julie.Refardt@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Refardt, Dr.</last_name>
      <phone>+41(0)61 2652525 Zentrale</phone>
      <email>julie.refardt@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Mirjam Christ-Crain, Prof</last_name>
      <email>mirjam.christ@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SGLT2-inhibitor</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Inappropriate ADH Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

